Literature DB >> 23300244

Increased risk of renal stones in patients treated with atazanavir.

Pierre Tattevin, Matthieu Revest, Jean-Marc Chapplain, Maja Ratajczak-Enselme, Cédric Arvieux, Christian Michelet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23300244     DOI： 10.1093/cid/cis1211

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

Review 1.  Kidney stones.

Authors:  Saeed R Khan; Margaret S Pearle; William G Robertson; Giovanni Gambaro; Benjamin K Canales; Steeve Doizi; Olivier Traxer; Hans-Göran Tiselius
Journal:  Nat Rev Dis Primers       Date:  2016-02-25       Impact factor: 52.329

2.  Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.

Authors:  Lene Ryom; Jens Dilling Lundgren; Peter Reiss; Ole Kirk; Matthew Law; Mike Ross; Phillip Morlat; Christoph Andreas Fux; Eric Fontas; Stephane De Wit; Antonella D'Arminio Monforte; Wafaa El-Sadr; Andrew Phillips; Camilla Ingrid Hatleberg; Caroline Sabin; Amanda Mocroft
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

Review 3.  Kidney Disease in HIV Infection.

Authors:  Gaetano Alfano; Gianni Cappelli; Francesco Fontana; Luca Di Lullo; Biagio Di Iorio; Antonio Bellasi; Giovanni Guaraldi
Journal:  J Clin Med       Date:  2019-08-19       Impact factor: 4.241

4.  Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania.

Authors:  Herry Mapesi; James Okuma; Fabian Franzeck; Herieth Ismael Wilson; Elizabeth Senkoro; Theonestina Byakuzana; Robert Ndege; Fiona Vanobberghen; Tracy Renée Glass; Manuel Battegay; Maja Weisser; Daniel Henry Paris
Journal:  PLoS One       Date:  2021-12-15       Impact factor: 3.240

5.  Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.

Authors:  Takeshi Nishijima; Yohei Hamada; Koji Watanabe; Hirokazu Komatsu; Ei Kinai; Kunihisa Tsukada; Katsuji Teruya; Hiroyuki Gatanaga; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

6.  A prediction model of Nephrolithiasis Risk: A population-based cohort study in Korea.

Authors:  David Mukasa; Joohon Sung
Journal:  Investig Clin Urol       Date:  2020-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.